ABSTRACT Genetically engineered plants incorporate the use of a novel bioreactor known as molecular pharming, which has a transformative view on the pharmaceutical industry. The technique enables mass production, at a low cost, and reproducibly of a large number of different protein‐based drugs, vaccines, and industrial enzymes. This review‐based study outlines the chronological evolution of molecular pharming, investigates its essential principles and elective applications, and meticulously compares it with other methods, namely conventional biomanufacturing. We present the numerous host organisms employed, the leading‐edge genetic engineering procedure, and the sophisticated approaches for protein purification and extraction. Additionally, we deliver in‐depth analysis of the noteworthy advantages that take place in molecular pharming as a captivating substitute, in conjunction with obstinate challenges, including concerns of public insights, intricate regulatory frameworks, and consideration for economic sustainability. Finally, this comprehensive study explores the promising direction, evolving innovations, and essential areas that influence future research to fully reveal the extensive potential of plant‐based biopharmaceutical production for industrial strains and global health.
Ahmed et al. (Sun,) studied this question.